What You Should Know:
– Eko Health, a leader in AI-powered cardiac and pulmonary care, today announced a major stride in expanding access to early heart disease detection. The Centers for Medicare & Medicaid Services (CMS) has included Eko’s SENSORA platform in its July 2025 provisional update to the Hospital Outpatient Prospective Payment System (OPPS), assigning SENSORA’s Category III CPT code to APC 5734, with a reimbursement rate of $128.90 per use.
– The Category III CPT code issued by the American Medical Association (AMA) for SENSORA will officially take effect on July 1, 2025, further signaling growing institutional recognition of the clinical utility of algorithmic cardiac support tools.
Addressing Diagnostic Gaps in Heart Disease
Heart disease remains the leading cause of death in the U.S., responsible for nearly 1 in 5 deaths, according to the CDC. Despite this, conditions such as low ejection fraction, valvular heart disease, and atrial fibrillation are frequently missed in routine exams, particularly in time-limited care settings.
SENSORA directly addresses these diagnostic gaps by delivering real-time AI analysis in under a minute. It enables earlier detection of structural murmurs, low ejection fraction (Low EF), and atrial fibrillation (AFib) using Eko’s ECG-enabled digital stethoscopes.
How SENSORA Integrates into Clinical Workflows
SENSORA is Eko Health’s FDA-cleared and clinically validated AI platform, bringing advanced cardiac analysis directly to the front lines of care. It integrates seamlessly with Eko’s digital stethoscopes, providing real-time, assistive insights during routine exams. This helps clinicians identify structural murmurs, low ejection fraction (Low EF), and atrial fibrillation (AFib) with increased confidence.
Designed for seamless implementation, SENSORA offers a scalable, point-of-care solution that improves early detection and bridges gaps in access to specialty-level cardiac evaluation. With the new CPT code effective July 1, 2025, Eko Health will expand reimbursement efforts and support widespread clinical adoption through collaborations with commercial payers, health systems, and public health agencies.
